Patient Advocate Says Novartis ' $475,000 Breakthrough Should Cost Just $160,000

David Mitchell, 67, says he ’s sure that Novartis’ Kymriah is a breakthrough medicine, and that he will need a similar medicine to treat his own blood cancer. He’s sure of something else, too: Novartis is charging too much.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: NYSE:NVS NASDAQ:CELG NASDAQ:GILD NASDAQ:JUNO Source Type: news